2017 International Meeting on Non-Alcoholic Fatty Liver Disease (NAFLD)

September 9 – 11, 2017
Hotel Fort Garry
Winnipeg, Manitoba
Canada

Presented By:

Sponsored By:

Canadian Association for the Study of the Liver (CASL)
Association Canadienne pour l’étude du foie (ACEF)

With Support From:

Canadian Liver Foundation
Fondation canadienne du foie

Version Date: 2017-07-18
(Subject to change without notice)
2017 International Meeting on Non-Alcoholic Fatty Liver Disease (NAFLD)

SCIENTIFIC CO-CHAIRS

Eberhard L. Renner
Past President CASL
Professor and Head
Department of Internal Medicine
Max Rady College of Medicine
University of Manitoba
Winnipeg, MB, Canada

Brent A. Neuschwander-Tetri
Professor of Internal Medicine
Director, Division of Gastroenterology and Hepatology
Director NASH Studies Unit
Saint Louis University School of Medicine
Saint Louis, MO, USA

LEARNING OBJECTIVES

In parallel with the obesity/diabetes epidemic, the incidence and prevalence of NAFLD continues to rise in Canada and elsewhere. While NAFLD leads to an increasing health care burden, our understanding and the therapeutic options remain limited. It is therefore imperative that the level of knowledge and understanding of this liver disease be increased. This will require a multi-pronged approach to adequately address it from prevention, diagnosis, management, treatment and research perspectives.

Upon completion of the conference, participants will be able to:

- Recognize the current status of epidemiology, pathophysiology, diagnosis, clinical presentation, and therapy of NAFLD.
- Identify gaps in our current understanding of NAFLD that need to be filled by future research.

Furthermore, the knowledge gained from this meeting can be applied and enhanced as the interactive format of the meeting will strive to:

- Foster informal exchange between leaders in the field and engage young investigators.
- Foster research collaboration on NAFLD within Canada, North America and beyond.
2017 International Meeting on Non-Alcoholic Fatty Liver Disease (NAFLD)

PARTICIPANTS

The 1.5-day education program aims to attract an estimated audience of 100 attendees with the target audience being

- Clinicians (of any background) interested in NAFLD
- Young investigators with an academic interest in NAFLD
- Scientists interested in NAFLD

ACCREDITATION

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by Canadian Association for the Study of the Liver.

Non-Canadian attendees may also qualify for credits as the Royal College of Physicians and Surgeons of Canada has established international agreements covering Maintenance of Certification with the following:

- American Medical Association (AMA)
- European Union of Medical Specialists (UEMS)
- Qatar Council for Healthcare Practitioners
- Accreditation Council for Continuing Medical Education (ACCME)

LOCATION / DATES / HOTEL RESERVATION

Location: Hotel Fort Garry
222 Broadway
Winnipeg, Manitoba R3C 0R3, Canada
Phone: (204) 942-8251

Dates: Saturday, September 9 to Monday September 11, 2017
- Day 1: Saturday Welcome Reception (evening)
- Day 2: Sunday Scientific Program/Dinner
- Day 3: Monday Scientific Program (morning - adjourn at noon)

Hotel Reservation: To secure meeting rates (CAD $159 + taxes per Queen, King or Double/Double room for single or double occupancy), book prior to August 8, 2017 by calling (204) 942-8251 or Toll Free 1-800-665-8088 and use meeting code (10V962). The number of reserved rooms is limited and will be sold on first come/first served basis.
REGISTRATION

Registration: On line registration available through CASL homepage (www.hepatology.ca) or click here.

Registration Fee (CAD $):

<table>
<thead>
<tr>
<th></th>
<th>Prior to June 30, 2017</th>
<th>From July 1, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>CASL members</td>
<td>$200</td>
<td>$250</td>
</tr>
<tr>
<td>Non-CASL members</td>
<td>$400</td>
<td>$450</td>
</tr>
<tr>
<td>Trainees</td>
<td>$100</td>
<td>$150</td>
</tr>
<tr>
<td>On-site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CASL members</td>
<td>$300</td>
<td></td>
</tr>
<tr>
<td>Non-CASL members</td>
<td>$500</td>
<td></td>
</tr>
<tr>
<td>Trainees</td>
<td>$200</td>
<td></td>
</tr>
</tbody>
</table>

For more information on how to become a CASL member, please visit www.hepatology.ca.
2017 International Meeting on Non-Alcoholic Fatty Liver Disease (NAFLD)

**SCIENTIFIC PROGRAM**

**Saturday, September 9, 2017**  
1900-2100  Welcome Reception, Hotel Fort Garry

**Sunday, September 10, 2017**

**SESSION I - CLINICAL**

**Learning Objectives**  
At the end of this session, participants will/will be able to
- describe the epidemiology of NAFLD
- explain the natural history of NAFLD
- identify the histopathological features and staging of NAFLD
- comprehend the diagnostic value of non-invasive tests in NAFLD
- recognize aspects of NAFLD specific to children

**Breakfast (will be provided)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800</td>
<td>Magnitude of the problem - epidemiologic overview</td>
<td>Jeanne-Marie Giard, CHUM, Montreal, QC</td>
</tr>
<tr>
<td>0830</td>
<td>Natural history, clinical/factors associated with progression of disease</td>
<td>Gerald Minuk, UM, Winnipeg</td>
</tr>
<tr>
<td>0900</td>
<td>Histopathological features and grading/staging</td>
<td>David Kleiner, NIH, Bethesda, MD</td>
</tr>
</tbody>
</table>

**Coffee Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1000</td>
<td>Non-invasive diagnostic tests (CAP Fibroscan, imaging, serological tests)</td>
<td>Keyur Patel, UHN, Toronto, ON</td>
</tr>
<tr>
<td>1030</td>
<td>The pediatric perspective</td>
<td>Eve Roberts, Dalhousie, Halifax, NS</td>
</tr>
</tbody>
</table>

**1100 Break-out sessions and report back**
- Which are the epidemiological and clinical knowledge gaps – which are the high priority areas for further study?
- How should we diagnose NASH in clinical practice – which are the most promising non-invasive approaches to be further developed/evaluated?
- Which are the most relevant endpoints for future interventional clinical trials?

**Lunch (will be provided)**
SESSION II – PATHOGENIC FACTORS

Learning Objectives
At the end of this session, participants will/will be able to
 explain the pathomechanisms involved in NAFLD
 recognize the genetic factors predisposing to NAFLD
 summarize the nutritional aspects in NAFLD
 describe the role of the gut microbiome in NAFLD
 identify cellular senescence as a potential link between NAFLD and HCC

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1400</td>
<td>Pathomechanisms leading to NAFLD – overview</td>
<td>Brent Neuschwander-Tetri, SLU, St Louis, MO</td>
<td></td>
</tr>
<tr>
<td>1430</td>
<td>Genetic polymorphisms predisposing to NASH</td>
<td>Anne Daly, Newcastle University, Newcastle, UK</td>
<td></td>
</tr>
<tr>
<td>1500</td>
<td>NAFLD and nutrition – is it just about calories?</td>
<td>Saumya Jayakumar, University of Calgary, AB</td>
<td></td>
</tr>
</tbody>
</table>

Coffee Break

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1600</td>
<td>NAFLD and the gut microbiome</td>
<td>Marialena Mouzaki, Children's Hospital, Cincinnati, OH</td>
<td></td>
</tr>
<tr>
<td>1630</td>
<td>Cellular Senescence: missing link between HCC and fatty liver disease?</td>
<td>Aloysious D. Aravinthan, Nottingham, UK</td>
<td></td>
</tr>
<tr>
<td>1700</td>
<td>Break-out sessions and report back</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

• which are the pathomechanistic knowledge gaps – which are the high priority areas for further studies?
• which mechanism(s) are potentially involved in governing transition from steatosis to steatohepatitis and merit further study?
• which pathomechanisms might serve as potential therapeutic targets?

Dinner (will be provided)
SCIENTIFIC PROGRAM - continued

Monday, September 11, 2017

SESSION III - THERAPY

Learning Objectives
At the end of this session, participants will/will be able to
- describe the value and limitations of life style measures in the treatment of NAFLD
- identify current and emerging pharmacotherapeutic treatment options
- recognize the role of bariatric surgery in NAFLD
- summarize the role and limitations of liver transplantation in NAFLD

Breakfast (will be provided)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800</td>
<td>Life Style measures</td>
<td>Kathleen Corey, Harvard/MGH, Boston, MA</td>
</tr>
<tr>
<td>0830</td>
<td>Current and emerging pharmacotherapeutic</td>
<td>Brent A. Neuschwander-Tetri, SLU, St. Louis, MO</td>
</tr>
<tr>
<td></td>
<td>treatment options</td>
<td></td>
</tr>
<tr>
<td>0900</td>
<td>The role of bariatric surgery</td>
<td>Stavra Xanthakos, Children’s Hospital, Cincinnati, OH</td>
</tr>
<tr>
<td>0930</td>
<td>Liver Transplantation</td>
<td>Kymberly Watt, Mayo Clinic, Rochester, MN</td>
</tr>
</tbody>
</table>

Coffee Break

<table>
<thead>
<tr>
<th>Time</th>
<th>Break-out sessions and report back</th>
</tr>
</thead>
<tbody>
<tr>
<td>1030</td>
<td>- which are the knowledge gaps with currently available therapeutic options</td>
</tr>
<tr>
<td></td>
<td>- which are the high priority areas for further studies</td>
</tr>
<tr>
<td></td>
<td>- how are life style measures best administered in clinical practice (setting)</td>
</tr>
<tr>
<td></td>
<td>- who will/should treat NAFLD today and in the future</td>
</tr>
</tbody>
</table>

Adjourn (1200) / Boxed Lunch (will be provided)

CONTACT INFORMATION

For information on the meeting, accreditation and registration, please contact:

Karen Kiel or Ingrid Reuter
Health Sciences Centre
GC430-820 Sherbrook Street
Winnipeg MB  R3A 1R9
Ph: 204-787-7770
Fax: 204-787-3159
E-mail: KKiel@exchange.hsc.mb.ca or IReuter@exchange.hsc.mb.ca
The Canadian Liver Foundation acknowledges the following organizations for their support of the CLF’s mission of “bringing liver research to life” to benefit the liver health of all Canadians through research, education, patient support and advocacy.

PLATINUM SPONSORS

- Gilead
- Intercept

BRONZE SPONSORS

- Astellas Pharma Canada Inc
- Novo Nordisk Canada Inc

EXHIBITORS / SUPPORTERS

- Advanced Care Specialty Pharmacy Network
- Alexion Pharma Canada
- Department of Medicine, University of Manitoba
- Canadian Institutes of Health Research - Institute of Nutrition, Metabolism & Diabetes
- GENFIT Corp.

In keeping with the Canadian Medical Association Guidelines, program content and selection of speakers are the sole responsibility of the Scientific Committee. Funders have had no input into the content, speakers or activities of this meeting.